SAN DIEGO, CALIFORNIA / ACCESS Newswire / February 25, 2026 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative ...
The Billionaire Bioscience Code is a wealth manifestation program that improves the financial portfolio of any user. The program includes three bonuses; all materials are instantly available after ...
Ensysce Biosciences (NASDAQ: ENSC) shares are up on Friday as the company has initiated a review of strategic alternatives aimed at enhancing shareholder value. The company on Wednesday announced that ...
Inhibrx Biosciences, Inc. is a high-risk, catalyst-driven biotech, with valuation hinging on the clinical success of ozekibart and INBRX-106. INBX reported an FY25 net loss of $140.1 million, ...
"Cernum Biosciences review 2026 highlights peptide purity testing, transparency standards, and third-party verification in research compounds"Cernum Biosciences has been recognized in a 2026 ...
Neurocrine Biosciences (NBIX) has decided to expand its previously very disappointing deal with Voyager Therapeutics (VYGR), this time focusing on Voyager’s next-generation capsids that are thought to ...
Neutrophils, long considered short-lived immune cells, can be therapeutically targeted when their appropriate subset and functional state are identified for the disease context LIfT BioSciences’ ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results